Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II epstein-barr virus-transformed T cells

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 3934-3943

  Ndour, Papa Alioune ^a   Brocqueville, Guillaume ^a   Ouk, Tan Sothéa ^a,b   Goormachtigh, Gautier ^a   Morales, Olivier ^a   Mougel, Alexandra ^a   Bertout, Julie ^a   Melnyk, Oleg ^a   Fafeur, Véronique ^a   Feuillard, Jean ^b   Coll, Jean ^a   Adriaenssens, Eric ^a  

^a UNIV LILLE   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN KINASE B; TRANSFORMATION EFFECTOR SITE 1; TRANSFORMATION EFFECTOR SITE 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS LATENCY;

APOPTOSIS; CELL LINE; CELL TRANSFORMATION, VIRAL; DOWN-REGULATION; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84861325351     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05747-11     Document Type: Article

References (47)

1. Adriaenssens E, et al. 2004. A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways. Oncogene 23: 2681-2693.
2. Bornkamm GW, et al. 2005. Stringent doxycycline-dependent control of gene activities using an episomal one-vector system. Nucleic Acids Res. 33:e137.
3. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. 1997. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J. Biol. Chem. 272:19777- 19784.
4. Devergne O, et al. 1998. Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J. Virol. 72:7900 -7908.
5. Devergne O, et al. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol. Cell. Biol. 16:7098 -7108.
6. Eliopoulos AG, Young LS. 2001. LMP1 structure and signal transduction. Semin. Cancer Biol. 11:435- 444.
7. Floettmann JE, Rowe M. 1997. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene 15:1851-1858.
8. Gires O, et al. 1999. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:3064 -3073.
9. Gires O, et al. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16:6131- 6140.
10. Goormachtigh G, et al. 2006. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-κB and JNK signaling pathways. J. Virol. 80:7382-7393.
11. Groux H, et al. 1997. Isolation and characterization of transformed human T-cell lines infected by Epstein-Barr virus. Blood 89:4521- 4530.
12. Herve M, et al. 1997. On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34:157-163.
13. Hong SS, Gay B, Karayan L, Dabauvalle MC, Boulanger P. 1999. Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology 262:163-177.
14. Izumi KM, et al. 1999. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor interacting protein (RIP) but does not induce apoptosis or require RIP for NF-κB activation. Mol. Cell. Biol. 19:5759 -5767.
15. Izumi KM, Kaye KM, Kieff ED. 1997. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc. Natl. Acad. Sci. U. S. A. 94:1447-1452.
16. Izumi KM, Kieff ED. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptorassociated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. U. S. A. 94:12592- 12597.
17. Jin Z, El-Deiry WS. 2006. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol. Cell. Biol. 26:8136-8148.
18. Karin M, Lin A. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3:221-227.
19. Kaye KM, Izumi KM, Kieff E. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U. S. A. 90:9150 -9154.
20. Kieff E. 1996. Epstein-Barr virus and its replication, p 2343-2396. In Fields BN, et al (ed), Fields virology. vol 2, 3rd ed. Lippincott-Raven, Philadelphia, PA.
21. Kim KR, et al. 2000. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 19: 1764-1771.
22. Kulwichit W, et al. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 95:11963-11968.
23. Le Clorennec C, et al. 2008. Molecular basis of cytotoxicity of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) in EBV latency III B cells: LMP1 induces type II ligand independent autoactivation of CD95/ Fas with caspase 8-mediated apoptosis. J. Virol. 82:6721- 6733.
24. Le Clorennec C, et al. 2006. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-κB, STAT1, and p53. Blood 107:2070 -2078.
25. Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C. 2003. Recruit-ment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity 18:655- 664.
26. Liebowitz D, Wang D, Kieff E. 1986. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:233-237.
27. Masy E, et al. 2002. Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation. J. Virol. 76:6460-6472.
28. Micheau O. 2003. Cellular FLICE-inhibitory protein: an attractive therapeutic target? Expert Opin. Ther. Targets 7:559 -573.
29. Micheau O, Tschopp J. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190.
30. Miller WE, Earp HS, Raab-Traub N. 1995. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J. Virol. 69:4390-4398.
31. Miyake A, et al. 2008. Induction of apoptosis in Epstein-Barr virusinfected B-lymphocytes by the NF-κB inhibitor DHMEQ. Microbes Infect. 10:748 -756.
32. Morris MA, Dawson CW, Young LS. 2009. Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol. 5:811- 825.
33. Muppidi JR, Tschopp J, Siegel RM. 2004. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21:461- 465.
34. Ndour PA, et al. 2010. Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1. Cell. Signal. 22:303-313.
35. Rickinson A, Kieff E. 2007. Epstein-Barr virus, p 2655-2700. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
36. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. 1997. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:6914-6925.
37. Schneider F, et al. 2008. The viral oncoprotein LMP1 exploits TRADD for signaling by masking its apoptotic activity. PLoS Biol. 6:e8.
38. Schneider-Brachert W, et al. 2004. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21:415- 428.
39. Schutze S, Schneider-Brachert W. 2009. Impact of TNF-R1 and CD95 internalization on apoptotic and antiapoptotic signaling. Results Probl. Cell Differ. 49:63- 85.
40. Sharma SV, et al. 2006. A common signaling cascade may underlie " addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10:425- 435.
41. Sharma SV, Settleman J. 2007. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21:3214 -3231.
42. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. 2001. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J. Biol. Chem. 276:27058 -27063.
43. Tsang NM, et al. 2003. Presence of the latent membrane protein 1 gene in nasopharyngeal swabs from patients with mucosal recurrent nasopharyngeal carcinoma. Cancer 98:2385-2392.
44. Uren AG, Pakusch M, Hawkins CJ, Puls KL, Vaux DL. 1996. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc. Natl. Acad. Sci. U. S. A. 93:4974-4978.
45. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680 -1683.
46. Wang D, Liebowitz D, Kieff E. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831- 840.
47. Zheng L, et al. 2006. Competitive control of independent programs of tumor necrosis factor receptor-induced cell death by TRADD and RIP1. Mol. Cell. Biol. 26:3505-3513.